Igc pharma highlights alzheimer's pipeline with encouraging preclinical data on igc-m3 and advancing phase 2 cannabinoid-based igc-ad1

Positions igc at the intersection of biotech innovation and cannabinoid science in one of the largest unmet medical needs in the world alzheimer's affects over 50 million people globally, with more than 400 million at risk from underlying disease pathology potomac, maryland / access newswire / august 12, 2025 / igc pharma, inc. ("igc" or the "company") (nyse american:igc) today announced promising preclinical results for igc-m3, a novel small molecule designed to address multiple biological drivers of alzheimer's disease. igc-m3 demonstrated activity in laboratory models against beta-amyloid aggregation, oxidative stress, mitochondrial dysfunction, and neuroinflammation, four key contributors to alzheimer's pathology.
IGC Ratings Summary
IGC Quant Ranking